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**Abstract**

The objectives of the current study were to determine the extent to which previously identifed increased expression of cytokines in a subgroup of individuals with schizophrenia (40%) relate to markers of oxidative stress, astrogliosis and grey matter volume reductions in postmortem tissue. We utilized a collection of dorsolateral prefrontal cortex tissue from 37 individuals with schizophrenia and 37 controls. Total glutathione was measured using a fluorometric assay. Protein levels of glutathione peroxidase (GPx) and the catalytic subunit of glutamate cysteine ligase (GCLC) were determined by Western blotting. Astrogliosis was assessed by measuring mRNA expression levels of glial fibrilliary acidic protein (GFAP) using qRT-PCR, and by examining the morphology of GFAP-positive astrocytes in immunostained sections. Cortical volumes were determined in a subset of 28 individuals with schizophrenia and 22 controls using photographs of fixed postmortem sections and Cavalieri's probe. GFAP mRNA, astrocyte morphology, GPx and GCLC protein levels were not significantly different between people with schizophrenia and controls overall. The diagnosis of schizophrenia was associated with decreased levels of reduced glutathione and reduced cortical volume. Individuals with schizophrenia who also had increased expression of inflammatory cytokines in the PFC displayed an exacerbated pathology, including decreased levels of reduced glutathione, increased GFAP mRNA, hypertrophic astrocyte morphology, and reduced grey matter volume, particularly in the superior frontal gyrus, relative to individuals with schizophrenia with low levels of inflammatory cytokines and unaffected controls. We conclude that the subgroup of individuals with schizophrenia who had elevated cytokines also show evidence of ongoing oxidative stress vulnerability and neurodegenerative processes such as astrogliosis and cortical volume loss. This has implications for clinical trials of novel therapeutics in schizophrenia, as membership of an inflammatory subgroup may influence treatment response.
